IA期肺腺癌病理高危因素及术后辅助化疗研究进展  

A Review on Pathological High-risk Factors and Postoperative Adjuvant Chemotherapy in Stage IA Lung Adenocarcinoma

作　　者：沈晨 方文涛[1] Chen SHEN;Wentao FANG(Department of Thoracic Surgery,Shanghai Chest Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200030,China)

机构地区：[1]上海市胸科医院,上海交通大学医学院附属胸科医院胸外科,上海200030

出　　处：《中国肺癌杂志》2022年第8期593-600,共8页Chinese Journal of Lung Cancer

摘　　要：早期非小细胞肺癌患者的生存率有待提高。含实体或微乳头成分、伴脉管侵犯或伴气道播散的浸润性腺癌患者属于复发风险高危人群,需要探索包括根治性手术切除在内的系统治疗方案。而现有指南不推荐IA期患者行术后辅助化疗。本文将综述上述病理高危因素在IA期肺腺癌患者中的研究进展以及辅助化疗在IA期复发风险高危人群中的作用。The survival rate needs to be improved in early stage non-small cell lung cancer patients."The risk of recurrence is relatively high in invasive adenocarcinoma patients with a solid or micropapillary component,lymphovascular invasion or tumor spread through air spaces.Systemic treatment options including radical surgical resection should be explored for this population.Adjuvant chemotherapy is not recommended for patients in stage IA in current guidelines.This article is a review on the research progress of the above pathological high-risk factors and the role of adjuvant chemotherapy in patients with patholo gical high-risk factors in stage IA lung adenocarcinoma.

关 键 词：肺肿瘤 病理学 预后 辅助化疗 

分 类 号：R734.2[医药卫生—肿瘤]